Immune Checkpoint Inhibitor

Questions discussed in this category

Is there evidence for development of more severe autoimmune toxicities for young patients vs older patients on immune checkpoint inhibitors?

As immune checkpoint inhibitors have expanded into the neoadjuvant breast cancer setting, severe and unexpected autoimmune toxicities may cause delays...

1 Answer available

In a patient with HER2+ advanced endometrial cancer, do you include IO(+/- olaparib) in their treatment regimen, or only trastuzumab in addition to carboplatin/paclitaxel?

Does your decision depend on MMR status? Would you use the same approach for neoadjuvant treatment?In light of relevant trials including RUBY, GY018, ...

3 Answers available

Would you recommend adjuvant chemo+IO +/- olaparib for patients with occult stage III disease identified after staging surgery with no measurable residual disease?

DUO-E, GY-018, and RUBY included patients with stage III and IV endometrial cancer WITH measurable disease.Would your decision change based on the mis...

4 Answers available

Can JAK inhibitors for established rheumatoid arthritis be continued when starting an immune checkpoint inhibitor?

2 Answers available

In mismatch repair deficient recurrent endometrial cancer eligible for single agent PD-1 inhibitor, do you prefer pembrolizumab or dostarlimab and why?

1 Answer available

In patients with advanced endometrial cancer who you plan to treat with chemotherapy + immunotherapy (per GY018 or RUBY), how and when do you utilize adjuvant EBRT and/or brachytherapy?

Does the presence of parametrial or cervical involvement impact your decision? How do you sequence treatment modalities?

3 Answers available

How do you schedule IV/PO Dexamethasone if giving immunotherapy concurrently with chemotherapy in patients with NSCLC?

1 Answer available

How would you manage immune check point inhibitor induced capillary leak syndrome refractory to IVIG monotherapy?

1 Answer available

Papers discussed in this category

J Clin Oncol, 2019 Nov 04

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

J Immunother Cancer, 2022 Jan

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.

J Clin Oncol, 2022 Jan 06

Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.

N Engl J Med, 2023 Mar 27

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

N Engl J Med, 2023 Mar 27

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.

Journal of clinical oncology : Official Journal of the American Society of Clinical Oncology, 2023 Oct 21

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.

Translational cancer research, 2021 May

Combination radiation and immunotherapy in gynecologic malignancies-a comprehensive review.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Lancet (London, England), 2023 Oct 20

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Oct 23

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.

The New England journal of medicine, 2018-05-31

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2018-11-22

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Journal for immunotherapy of cancer, 2022 Jan

Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition.

Clinical rheumatology, 2020 Sep 28

Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?

Frontiers in immunology, 2022 Sep 15

Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib.

Cancer cell, 2022 May 09

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.

Related Topics